ANI Pharmaceuticals, Inc. — Drug Manufacturers - Specialty & Generic. Scored on the same transparent 7-signal model behind the daily rankings.
★
ANIP
ANI Pharmaceuticals, Inc. · Drug Manufacturers - Specialty & Generic
FCF$191mC
Rev+43.8%A
D/E1.12C
P/E21.7xB+
PEG0.49A
83.7Score
$83.78$1.9B
1Y Target$112.71Analyst consensus · 7 analysts
5Y Target$142.30Compound horizon
10Y Target$182.50Long-dated conviction
FCF$191mTTMC
FCF $191m — modest; watch for margin expansion
Rev+43.8%TTM YoYA
Revenue +43.8% — hypergrowth, top decile
D/E1.12C
D/E 1.12 — more levered than most Healthcare peers (≈90th pctile)
P/E21.7xB+
P/E 21.7 — below the Healthcare median (≈40th pctile)
PEG0.49proxyA
PEG 0.49 — exceptional; paying well under fair value for growth · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 83.7
Quality0.64
Growth1.00
Value0.91
Entry · Margin of safety
52-week rangeMid-range
16% off the 12-month high
vs DCF fair value47% belowest. fair value ~$158
Quality signals · context only
Gross profitability59% · Agross profit ÷ total assets (Novy-Marx)
ROIC11.3% · Breturn on invested capital — not score-weighted
Why now
ANI Pharmaceuticals is a compelling growth compounder, demonstrating exceptional operational leverage as it expands its diversified portfolio of branded products, including Cortrophin gel, ILUVIEN, and YUTIQ, alongside its robust generic offerings. With a staggering 43.8% FY YoY revenue growth and an incredibly attractive 0.5 PEG ratio, the market is clearly underpricing its future earnings power. The company's ability to generate $191m in TTM free cash flow underscores its financial strength to fuel further product development and market penetration.
Moat
ANI Pharmaceuticals' durable edge stems from its integrated biopharmaceutical model, encompassing the development, manufacturing, and marketing of a wide array of complex products, from injectables and softgel capsules to specialized branded offerings like Cortrophin gel. This broad capability, including manufacturing controlled substances and potent products, creates significant barriers to entry for competitors. Its extensive distribution network, reaching national wholesalers, specialty pharmacies, and hospitals, further solidifies its market position and ensures consistent access for its diverse product lines.
Risk
Skeptics would point to ANI Pharmaceuticals' elevated 1.12 debt-to-equity ratio as a significant overhang, suggesting that its aggressive growth strategy might be overleveraged. This debt could become a substantial burden if the company faces increased competition in its generic pharmaceutical segments or if its key branded products like Cortrophin gel encounter unexpected market headwinds, leading to revenue deceleration. A sustained contraction in the 9.9% profit margin, alongside further increases in the debt load, would confirm the bear case, indicating that the company's growth is coming at an unsustainable cost.
Horizon
1-3 yr $112.71 (7-analyst consensus) — multiple re-rating thesis requires a catalyst. 5 yr $142.30 at ~11% CAGR — dividend + buyback compounding. 10 yr $182.50 if the moat survives secular pressure.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Position sizing · ANIP
$
%
%
Shares to buy
23
Position size
$1,927
3.9% of portfolio
Stop price
$62.84
25% below $83.78
$ at risk if stopped
$481.74
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
ANI Pharmaceuticals, Inc. (ANIP): score, valuation & FAQ
ANI Pharmaceuticals, Inc. (ANIP) is a Drug Manufacturers - Specialty & Generic company that scores 83.7 out of 100 on the Bull Rankings quality-growth model — a strong reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are Rev (A), PEG (A) and P/E (B+). On valuation, ANIP sits about 47% below our discounted-cash-flow fair value (a margin of safety).
Is ANIP a good stock to buy?
Bull Rankings scores ANIP 83.7 out of 100 on its quality-growth model, which is a strong reading. That is driven by Rev (A), PEG (A) and P/E (B+). A score is a quantitative screen of ANI Pharmaceuticals, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does ANIP score 83.7 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). ANIP earns its highest marks on Rev (A), PEG (A) and P/E (B+). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is ANIP overvalued or undervalued?
Based on $83.78, ANIP sits about 47% below our discounted-cash-flow fair value (a margin of safety). It trades at a 21.7x× P/E (graded B+). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in ANIP?
Skeptics would point to ANI Pharmaceuticals' elevated 1.12 debt-to-equity ratio as a significant overhang, suggesting that its aggressive growth strategy might be overleveraged. This debt could become a substantial burden if the company faces increased competition in its generic pharmaceutical segments or if its key branded products like Cortrophin gel encounter unexpected market headwinds, leading to revenue deceleration. A sustained contraction in the 9.9% profit margin, alongside further increases in the debt load, would confirm the bear case, indicating that the company's growth is coming at an unsustainable cost.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.